Maher Albitar, M.D.

Chief Medical Officer, Director, Research and Development, NeoGenomics Laboratories

"Almost all therapeutic agents are currently being developed with a specific target in mind, and clinical trials, in general, consider testing and measuring this target."

Andrea Ferreira-Gonzalez, Ph.D.

Pathologist, VCU Massey Cancer Center; Chair, Molecular Diagnostics Division, VCU Health

"A new type of immunotherapy known as chimeric antigen receptor-modified (CAR) T-cell therapy is beginning to look promising for some forms of cancer."

John Leite, Ph.D.

Vice President, Oncology, Illumina

"We’re seeing an increase in the formation of research consortia that drive collaboration amongst the top minds in the field."

Jim Godsey

Vice President, Research and Development, Clinical NGS and Oncology, Thermo Fisher Scientific

"Sophisticated gene panels are now available to analyze very small amounts of tumor samples for hundreds of mutations using targeted next-generation sequencing (NGS)."